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Abstract In neuroblastoma LAN-5 cells during calpain activa-
tion, in addition to the two expressed 70 kDa and 30 kDa
calpastatin forms, other inhibitory species are produced, having
molecular masses of 50 kDa and 15 kDa. At longer times of
incubation, both native and new calpastatin species disappear.
The formation of these new calpastatins as well as the decrease in
intracellular total calpastatin activity are mediated by calpain
itself, as indicated by the effect of the synthetic calpain inhibitor
I, which prevents both degradative processes. Analysis of the
calcium concentrations required for the two processes indicates
that the first conservative proteolytic event is mediated by
W-calpain, whereas the second one is preferentially carried out by
m-calpain. The appearance of the 15 kDa form, containing only
the calpastatin repetitive inhibitory domain and identified also in
red cells of hypertensive rats as the major inhibitor form, can be
considered a marker of intracellular calpain activation, and it can
be used for the monitoring of the involvement of calpain in
pathological situations. ß 2000 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Calpain belongs to a family of thiol-proteinases having an
absolute requirement for Ca2 ions [1^3]. Although many
calpain isoforms have been identi¢ed, those most relevant
seem to be the ubiquitary isozymes called W-calpain and m-
calpain, requiring low and high calcium concentrations, re-
spectively. These proteinases are present in all mammalian
tissues and are involved in a variety of processes including
cell proliferation [4,5], di¡erentiation [6^8], vesicle secretion
and others [9,10].
Both calpain isozymes reside in the cell cytosol in an inac-
tive conformation that is converted into the active one by an
intramolecular process triggered by the binding of calcium
ions to speci¢c sites localised in the calmodulin-like domain.
The initial Ca2-induced conformational change promotes
both the organisation of essential amino acidic residues at
the active site and the removal of a segment from its N-ter-
minal region, a process occurring in two autoproteolytic steps.
The digested calpain form requires much less Ca2, as com-
pared to the native form. This activation process is favoured
by phospholipids [11,12], activator proteins [13,14] and me-
tabolites [15]. The negative natural modulator is a protein
called calpastatin [1^3]. This protein is characterised by a
peculiar molecular structure [16] having four repetitive inhib-
itory domains and the N-terminal domain (L-domain) whose
function has not yet been de¢ned. In rat brain, multiple cal-
pastatin forms are constitutively expressed; the more repre-
sented species are a 70 kDa form containing in addition to
L-domain four repetitive domains, and a truncated form
(V30 kDa) having just one inhibitory domain [17^20].
More recently, we have observed that in various cellular types
calpastatin is aggregated in a speci¢c cell region and is re-
leased from its association by an increase in intracellular
[Ca2] [21]. Hence, the same signal inducing calpain activation
is also involved in a redistribution of calpastatin, a process
required for the formation of the enzyme^inhibitor complex
with the native as well as the activated calpain forms.
Furthermore, calpastatin can be digested by calpains [22^
24]. Evidence in favour of this speci¢c proteolysis has been
collected both in vitro and in vivo experiments. In recon-
structed systems, it has been demonstrated that W-calpain
slowly digests calpastatin, without loss of inhibitory e⁄ciency.
On the contrary, m-calpain produces a more dramatic diges-
tion of calpastatin, yielding inactive fragments [24]. A loss of
calpastatin activity has been reported in di¡erent pathological
conditions, including essential hypertension both in humans
[25] and in genetic hypertensive rats of Milan strain [26,27]. In
this disease, it has been postulated an intracellular increase in
Ca2 leading to cellular changes, including cell shape, and
volume [28]. However, in patients treated for long times
with anti-hypertensive drugs, together with the normalisation
of arterial blood pressure, an increase in calpastatin to control
levels has been detected [29]. These data suggest that a pro-
teolytic process is responsible for these changes.
We have now analysed, at the molecular level, calpastatin
degradation processes occurring in neuronal cells following an
increase in intracellular [Ca2]. Characterisation of those
processes leading to calpastatin fragmentation and inactiva-
tion may be relevant for the identi¢cation of the involvement
of calpain also in the triggering of pathological conditions.
2. Materials and methods
2.1. Materials
Human neuroblastoma LAN-5 cells were cultured as reported pre-
viously [30]. Ca2-ionophore A23187, leupeptin and phenylmethylsul-
fonyl£uoride (PMSF) were purchased from Sigma Chem. Co. Calpain
inhibitor I [31] was purchased from Boehringer Mannheim. Calpain
inhibitor I was found to be equally e¡ective in inhibiting both W- or
m-calpain isolated from rat brain. W-Calpain and m-calpain were pu-
ri¢ed from rat brain, as previously described [24].
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2.2. Preparation of homogenates from LAN-5 cells
LAN-5 cells were cultured in RPMI medium containing 15% foetal
calf serum in 75 cm2 £asks. Con£uent cells were exposed to 0.25 WM
Ca2-ionophore A23187 for di¡erent times of incubation or in the
presence of di¡erent Ca2 concentrations. If not speci¢cally indicated,
the experiments were performed in RPMI medium, which contains
0.42 mM Ca2, without any Ca2 addition. After incubation, cells
were rapidly washed three times with phosphate saline bu¡er, and
harvested with 3 ml of 50 mM sodium borate bu¡er pH 7.5 contain-
ing 0.1 mM EGTA and 0.5 mM L-mercaptoethanol (bu¡er A). Cell
suspensions were sonicated (four bursts of 10 s each) in the presence
of 0.1 mg/ml leupeptin and 2 mM PMSF. The particulate material
was discarded by centrifugation at 100 000Ug for 15 min. Finally, the
clear solution was heated for 3 min at 90‡C, centrifuged and the
supernatant (heated homogenate) was used as indicated.
2.3. Preparation of homogenates from erythrocytes of normotensive and
hypertensive rats
Erythrocytes from normotensive and hypertensive rats were lysed in
three volumes of bu¡er A containing 0.1 mg/ml leupeptin and 2 mM
PMSF and centrifuged at 100 000Ug for 15 min. The supernatants
were heated at 90‡C for 3 min, centrifuged at 100 000Ug for 15 min
and the soluble materials were submitted to sodium dodecyl sulfate
(SDS)^PAGE as described below.
2.4. Identi¢cation of calpastatin species on SDS^PAGE
Aliquots (500 Wg) of heated homogenates prepared from LAN-5 or
rat erythrocytes (see above) were submitted to 10% SDS^PAGE. At
the end of the electrophoretic run, the gel was washed to remove SDS,
and then cut in 0.3 cm slices [24]. Each slice was extracted with 0.3 ml
of bu¡er A for three times and the solutions obtained from each
sample were pooled. This procedure recovers almost completely the
protein loaded into the gel. Finally, calpastatin activity was assayed
on 200 Wl of the recovered solutions using human erythrocyte calpain,
being this enzyme highly sensitive to native and post-translational
modi¢ed calpastatins [24]. Consequently, the inhibition measured in
these conditions re£ects the actual amounts of calpastatin present in
the assay mixture. One unit of calpastatin is de¢ned as the amount
required to inhibit one unit of enzyme activity. One unit of enzyme
activity is de¢ned as the amount that releases 1 Wmol/h of free
K-amino groups under the speci¢ed conditions.
2.5. Radioimmunoassay of calpastatin on SDS^PAGE slices
Aliquots of the solution obtained following SDS^PAGE extraction
were used to determine calpastatin concentration with a solid-phase
radioimmunoassay [32]. A 96 well plate was coated with 100 Wl of
each sample of extracted material and was incubated overnight at
4‡C. The solution was removed, and the wells were blocked with
5% skim milk powder dissolved in phosphate saline bu¡er. After three
washings, 100 Wl of monoclonal antibody (mAb) 35.23 speci¢c for the
L-region of calpastatin [20] was added to each well and incubated for
2 h. After three washes with phosphate saline bu¡er, an anti-mouse
iodinated antibody was used to detect the formation of calpastatin^
mAb complex.
2.6. N-Terminal sequence analysis of 15 kDa calpastatin
SDS^PAGE-extracted 15 kDa calpastatin was lyophilised, sus-
pended in water containing 20% acetonitrile and loaded on the Beck-
man LF 3000 protein sequencer to determine primary structure.
3. Results
To identify the in vivo modi¢cations of calpastatin which
occur following calpain activation, we have used as model
LAN-5 neuroblastoma cells, because neuronal cells seem
highly sensitive to damages induced by the calcium-dependent
proteolytic system.
As shown in Fig. 1, following addition of A23187 to the cell
medium, total calpastatin activity, directly assayed on lysates
previously heated to inactivate calpain, increases 1.3^1.4-fold
during the ¢rst 30 min of incubation. At longer times, it pro-
gressively decreases, reaching values corresponding to 40% of
the original total activity, at the end of the incubation (120
min). Addition of the synthetic calpain inhibitor I [31] pre-
vents almost completely the disappearance of calpastatin ac-
tivity, but it has little or no appreciable e¡ect on the increase
of inhibitory activity observed at shorter times of incubation.
It can be speculated that the biphasic behaviour of calpastatin
is the result of two sequential processes generating ¢rst free
inhibitory domains [24] followed by a non-speci¢c degrada-
tion which completely inactivates the inhibitor protein.
To better explore the possible in vivo calpain-mediated pro-
teolysis of calpastatin, we have analysed calpastatin molecular
species present in LAN-5 cells, by submitting the heated ho-
mogenates to SDS^PAGE. As shown in Fig. 2A, in untreated
LAN-5 cells, two major peaks of calpastatin activity were
detected. The ¢rst one has a molecular weight of approxi-
mately 70^75 kDa and the second one of approximately
30 kDa. Both forms are recognised in Western blot by an
anti-calpastatin antibody raised against the L-domain of rat
brain calpastatin (Fig. 2A, inset). Based on the electrophoretic
mobility, and on the recognition by anti-calpastatin antibody,
the ¢rst calpastatin form corresponds to the native entire cal-
pastatin molecule and the second form is similar to a 30 kDa
calpastatin form, which is expressed in rat brain [20] and
consisting of the L-domain and a single inhibitory domain.
Preincubation of LAN-5 cells with the synthetic calpain in-
hibitor I (Fig. 2A, un¢lled circles) has no e¡ect on the nature
and on the levels of calpastatin, indicating that these forms
are constitutively expressed also in these cells. Following 30
min of incubation in the presence of ionophore A23187 (Fig.
2B), calpastatin is now recovered in four major peaks. Two of
these forms (70 kDa and 30 kDa) correspond to those ex-
pressed in untreated cells ; the other two (50 kDa and
15 kDa) are new species presumably resulting from the deg-
Fig. 1. E¡ect of calcium loading in LAN-5 cells on levels of calpas-
tatin activity. LAN-5 cells were preincubated for 1 h at 37‡C in the
absence (¢lled circles) or in the presence of 50 WM calpain inhibitor
I (un¢lled circles). The cells were then treated with 0.25 WM Ca2-
ionophore for the indicated times. After incubation, heated homoge-
nates were prepared as described in Section 2. Before the assay of
calpastatin activity, an aliquot (0.5 ml) of heated homogenates was
rapidly ¢ltered through a Superdex G25 column (1U10 cm) in order
to remove the synthetic low Mr proteinases inhibitors. Protein was
collected in a single fraction (approximately 2.5 ml) and calpastatin
activity was then assayed as described in Section 2 using human
erythrocyte calpain.
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radation of the native forms. This hypothesis is supported by
the e¡ect of the synthetic calpain inhibitor I, which, once
added to cell incubation medium, prevents almost completely
the appearance of both 50 kDa and 15 kDa fragments. At
longer times of incubation (Fig. 2C), the four calpastatin
forms are still present although in signi¢cantly lower
amounts; in these conditions, more than 60^65% of calpasta-
tin is inactivated. Again, addition of synthetic calpain inhib-
itor I largely prevents the disappearance of native calpastatin
forms. To better characterise these degraded fragments, we
have analysed their ability to interact with the anti-calpastatin
antibody directed against their calpastatin L-domain [21] (Fig.
2D). The ¢rst three calpastatin forms are recognised quanti-
tatively by a solid-phase radioimmunoassay, indicating that
these fragments contain the N-terminal domain and a di¡er-
ent number of repetitive inhibitory domains. However, the
form having the lowest molecular mass (15 kDa) is unable
to interact with the antibody and corresponds to a free repet-
itive inhibitory domain.
Further molecular analysis of this SDS^PAGE-extracted
15 kDa calpastatin form on FPLC, carried out by gel ¢ltra-
tion on a Superdex 75 column, has revealed that together with
a 15 kDa protein some other fragments with lower mass are
present (data not shown). The N-terminal amino acid se-
quence, carried out on this peptide mixture, resulted to be:
Pro-Asp/Glu-Pro. This sequence is repeated three times in rat
brain calpastatin [20] and the sizes of the putative fragments
formed are in agreement with the molecular masses of the
active calpastatin fragments obtained from LAN-5 cells.
This selective cleavage of calpastatin shows a functional sig-
ni¢cance, since the isolated free inhibitory domain displays a
from 4- to 7-fold higher inhibitory e⁄ciency against both
homologous W- and m-calpains, suggesting the degradation
process is involved also in an ampli¢cation of the cell inhib-
itory capacity.
In order to establish if the in vivo biphasic behaviour of
calpastatin digestion is due to the action of one or the other
calpain isozyme, we have analysed the formation and the dis-
appearance of the 15 kDa fragment in the presence of increas-
ing Ca2 (Fig. 3). At [Ca2] between zero and 20 WM, an
Fig. 2. Identi¢cation of calpastatin species in LAN-5 cells. A:
LAN-5 were incubated for 1 h in the absence (¢lled circles) or in
the presence of 50 WM synthetic calpain inhibitor I (un¢lled circles),
then heated homogenates were prepared as described in Section 2.
Calpastatin species were separated by SDS^PAGE and their activity
was assayed using 200 Wl of extracted protein as described in Sec-
tion 2. Inset: The two peaks of calpastatin activity extracted from
the gel were collected and separately submitted to another SDS^
PAGE. A Western blot analysis was performed to detect calpastatin
protein using mAb 35.23. B and C: Identi¢cation of calpastatin spe-
cies in calcium-enriched cells. Cells incubated as in A were exposed
to 0.25 WM Ca2-ionophore A23187 for 30 min or 120 min, respec-
tively, then lysed. Calpastatin species were separated and assayed as
in A. Filled circles indicate the incubations performed in the ab-
sence of calpain inhibitor, un¢lled circles those containing calpain
inhibitor I. D: Immunoidenti¢cation of calpastatin species in calci-
um-enriched cells. Aliquots (100 Wl) of the material extracted from
each gel slice obtained in C were submitted to a solid radioimmuno-
assay using anti-calpastatin mAb 35.23 (see Section 2). Un¢lled
symbols refer to radioactivity recovered in each well, ¢lled symbols
to calpastatin activity.
Fig. 3. Accumulation of intracellular 15 kDa calpastatin form as a
function of increasing Ca2 concentrations. LAN-5 cells were incu-
bated as described in Section 2 for 120 min at 37‡C in the presence
of 0.25 WM ionophore and the indicated [Ca2]. [Ca2] was estab-
lished by the addition to the medium of appropriate amounts of
EGTA [38]. Each sample was processed as reported in Section 2
and in Fig. 2. Calpastatin activity was measured using human eryth-
rocyte calpain.
Fig. 4. Identi¢cation of calpastatin species in erythrocytes of normo-
tensive and hypertensive rats. Heated homogenates prepared from
erythrocytes of normotensive and hypertensive rats were submitted
to SDS^PAGE and after the electrophoretic run, the gel was pro-
cessed as described in Section 2. Filled circles: hypertensive rats;
un¢lled circles: normotensive rats.
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increase in the amount of the 15 kDa fragment is observed,
whereas, as expected, at [Ca2] higher than 20 WM, a progres-
sive loss of this low molecular weight calpastatin form occurs.
Altogether, these observations indicate that the two phases of
calpastatin degradation process are mediated by di¡erent cal-
pain isozymes. Speci¢cally, W-calpain is active at lower [Ca2]
and is preferentially involved in the generation of the 15 kDa
fragment, whereas m-calpain, requiring much higher [Ca2], is
involved in a non-speci¢c calpastatin digestion which causes
the loss of inhibitory activity.
In vivo fragmentation of calpastatin has been identi¢ed also
in red cells of hypertensive rats. As shown in Fig. 4, when
calpastatin from erythrocyte lysates of normotensive rats is
analysed in SDS^PAGE as above, a single calpastatin form
has been detected showing a migration corresponding to a
molecular mass of approximately 75 kDa. However, in cells
from hypertensive rats, the native 75 kDa calpastatin is
largely reduced and only partially replaced by 10^15 kDa still
active calpastatin fragments. These data indicate that conser-
vative fragmentation and degradation of calpastatin occur in
cells in which calcium concentration increases for longer
times, as it happens in erythrocytes of these hypertensive ani-
mals.
4. Discussion
In this paper, we demonstrate that degradation of calpas-
tatin, previously observed in vitro [22^24], occurs in vivo fol-
lowing a prolonged activation of calpains. In the early phase,
the process seems to be operating in order to promote an
ampli¢cation of the inhibitory e¡ect of calpastatin, required
to block all activated calpain molecules generated in these
conditions. This salvage is produced by the preferential action
of W-calpain, which both in vitro and in vivo conservatively
degrades calpastatin promoting the formation of free calpas-
tatin repetitive domains. The ampli¢cation process derives not
only from an increase in the number of polypeptides showing
calpain inhibitory activity, but also by the fact that the iso-
lated, naturally generated repetitive fragments are more active
than the native entire calpastatin molecule.
The second phase, in which calpastatin is further and com-
pletely degraded, is carried out by m-calpain and occurs at
higher [Ca2].
The direct involvement of calpain in this digestion is sup-
ported by previously in vitro experiments and also by the in
vivo e¡ect of the synthetic calpain inhibitor I, which prevents
both fragmentation and digestion of calpastatin. In vivo deg-
radation of calpastatin by calpain is also reported in apoptotic
cells [33] although no evidence is provided on the formation of
free inhibitory domains during this process. The existence on
calpastatin molecules of sites speci¢cally recognised by pro-
teinases has also been demonstrated exposing in vitro native
calpastatin to thrombin, which produces a fragmentation sim-
ilar to that observed with W-calpain (data not shown), or with
caspase which promotes the degradation of calpastatin during
cell apoptosis [34,35]. Calpain-mediated calpastatin degrada-
tion is also reported in post-mortem bovine muscle [36]. This
digestive process could be interpreted as an ampli¢cation of
the inhibitory capacity in the cells, being a single calpastatin
molecule able to produce more than one free inhibitory do-
main.
The conservative degradation of calpastatin occurs only at
low [Ca2], indicating that W-calpain is preferentially involved
in this process. The non-speci¢c digestion accompanied by
loss of inhibitory activity requires longer times of incubation
or high [Ca2], suggesting the involvement of m-calpain, as
indicated also by the e¡ect of these proteinases in in vitro
experiments [37].
Furthermore, fragmentation and degradation of calpastatin
has been detected in red cells of hypertensive rats, which con-
tain a calpain form particularly e¡ective in degrading calpas-
tatin [24]. Disappearance of calpastatin activity requiring large
increases in [Ca2] or during longer times of incubation seems
related to the triggering of the ‘pathological role of calpains’,
a situation in which the regulatory machinery and the pro-
teinase component of the calcium-dependent proteolytic sys-
tem become unbalanced. The easier calpain activation occur-
ring after calpastatin degradation seems involved in the
production of cell damages such as cytoskeleton degradation,
ion pump digestion, changes in shape and volume of the cells,
identi¢ed in di¡erent pathological conditions. Hence, the iden-
ti¢cation of 15 kDa calpastatin fragment may characterise
conditions preceding the onset of this pathological role of
calpain and may be important to establish other situations
in which the proteinase can produce cell damages.
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